Randy Milby, CEO of Hillstream BioPharma (NASDAQ:HILS), was a guest on Benzinga’s All-Access.

Hillstream BioPharma is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug-resistant and devastating cancers. The company’s emerging immuno-oncology pipeline is led by HSB-3215.

The company recently teamed up with Minotaur Therapeutics to license one of its key technologies. The tech will allow Hillstream to create more targeted and efficient therapies and advance its drug pipeline more rapidly.

Watch here:

Featured photo by National Cancer Institute on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.